New Drug Approvals 2012 - Pt. XV - Carfilzomib (Kyorolis<sup>TM</sup> )
Carfilzomib | Kyprolis | PR-171 | CAS#868540-17-4 | 20S proteasome inhibitor | MedKoo Biosciences
Systemic Therapy for Cancer | SpringerLink
Exhibitor - Amgen - Virtual Exhibit Hall - Hematology Review 2021 | Mayo Clinic School of Continuous Professional Development
D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl- | C36H54N6O5 - PubChem
carfilzomib - Wikidata
Arenastatin A | C34H42N2O8 - PubChem
Carfilzomib | C40H57N5O7 - PubChem
Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma | PLOS ONE
Carfilzomib: new treatment for multiple myeloma | MIMS online
SMC approves Amgen's carfilzomib for multiple myeloma treatment - Pharmaceutical Technology
carfilzomib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period - Sun Hee Kim, Irene Krämer, 2019
NICE recommends Amgen's carfilzomib with dexamethasone for RMM treatment - Pharmaceutical Technology
KU has heavy hand in creation of Remdesivir
![Carfilzomib [PR-171] | CAS 868540-17-4 - Order from Adipogen Life Sciences](https://adipogen.com/pub/media/catalog/product/cache/image/700x560/e9c3970ab036de70892d86c6d221abfe/a/g/ag-cr1-3669.png "Carfilzomib [PR-171] | CAS 868540-17-4 - Order from Adipogen Life Sciences")
Carfilzomib [PR-171] | CAS 868540-17-4 - Order from Adipogen Life Sciences
PharmaWiki - Carfilzomib
carfilzomib - Wikidata
How to pronounce Kyprolis | HowToPronounce.com
US7402564B1 - Synthetic peptide amides - Google Patents
Amgen gets cosier with Dr. Reddy's, adding three marketed drugs to Indian partnership | Fierce Pharma
Elotuzumab | New Drug Approvals
KRd Plus Lenalidomide Maintenance Yielded Positive MRD- CRs and May Delay End-Organ Disease in High-Risk Smoldering Myeloma
